{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:15:41Z","timestamp":1790874941600,"version":"4.1.0"},"reference-count":293,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00787-011-0163-7","type":"journal-article","created":{"date-parts":[[2011,3,28]],"date-time":"2011-03-28T09:38:26Z","timestamp":1301305106000},"page":"173-196","source":"Crossref","is-referenced-by-count":369,"title":["European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment"],"prefix":"10.1007","volume":"20","author":[{"name":"the ESSTS Guidelines Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"Roessner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin J.","family":"Plessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aribert","family":"Rothenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea G.","family":"Ludolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liselotte","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Termine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter J.","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,29]]},"reference":[{"key":"163_CR1","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/appi.ajp.158.6.968-a","volume":"158","author":"FS Abuzzahab","year":"2001","unstructured":"Abuzzahab FS, Brown VL (2001) Control of Tourette\u2019s syndrome with topiramate. Am J Psychiatry 158:968","journal-title":"Am J Psychiatry"},{"key":"163_CR2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/104454604773840562","volume":"14","author":"MT Acosta","year":"2004","unstructured":"Acosta MT, Castellanos FX (2004) Use of the \u201cinverse neuroleptic\u201d metoclopramide in Tourette syndrome: an open case series. J Child Adolesc Psychopharmacol 14:123\u2013128","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mds.870110114","volume":"11","author":"CH Adler","year":"1996","unstructured":"Adler CH, Zimmerman RS, Lyons MK, Simeone F, Brin MF (1996) Perioperative use of botulinum toxin for movement disorder-induced cervical spine disease. Mov Disord 11:79\u201381","journal-title":"Mov Disord"},{"key":"163_CR4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.parkreldis.2007.10.007","volume":"14","author":"M Aguirregomozcorta","year":"2008","unstructured":"Aguirregomozcorta M, Pagonabarraga J, Diaz-Manera J, Pascual-Sedano B, Gironell A, Kulisevsky J (2008) Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck. Parkinsonism Relat Disord 14:443\u2013445","journal-title":"Parkinsonism Relat Disord"},{"key":"163_CR5","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000188869.58300.a7","volume":"65","author":"AJ Allen","year":"2005","unstructured":"Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, Winner PK, Dunn DW, Dure LS, Sallee FR, Milton DR, Mintz MI, Ricardi RK, Erenberg G, Layton LL, Feldman PD, Kelsey DK, Spencer TJ (2005) Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 65:1941\u20131949","journal-title":"Neurology"},{"key":"163_CR6","first-page":"22","volume":"62 (Suppl 7)","author":"DB Allison","year":"2001","unstructured":"Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62 (Suppl 7):22\u201331","journal-title":"J Clin Psychiatry"},{"key":"163_CR7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1176\/jnp.2008.20.3.375","volume":"20","author":"Y Arana-Lechuga","year":"2008","unstructured":"Arana-Lechuga Y, Sanchez-Escandon O, de Santiago-Trevino N, Castillo-Montoya C, Teran-Perez G, Velazquez-Moctezuma J (2008) Risperidone treatment of sleep disturbances in Tourette\u2019s syndrome. J Neuropsychiatry Clin Neurosci 20:375\u2013376","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"163_CR8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/088307389901400508","volume":"14","author":"Y Awaad","year":"1999","unstructured":"Awaad Y (1999) Tics in Tourette syndrome: new treatment options. J Child Neurol 14:316\u2013319","journal-title":"J Child Neurol"},{"key":"163_CR9","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/mds.20385","volume":"20","author":"Y Awaad","year":"2005","unstructured":"Awaad Y, Michon AM, Minarik S (2005) Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord 20:714\u2013718","journal-title":"Mov Disord"},{"key":"163_CR10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00787-007-1002-8","volume":"16 (Suppl 1)","author":"T Banaschewski","year":"2007","unstructured":"Banaschewski T, Neale BM, Rothenberger A, Roessner V (2007) Comorbidity of tic disorders & ADHD: conceptual and methodological considerations. Eur Child Adolesc Psychiatry 16 (Suppl 1):5\u201314","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"163_CR11","first-page":"I102","volume":"13 (Suppl 1)","author":"T Banaschewski","year":"2004","unstructured":"Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A (2004) Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 13 (Suppl 1):I102\u2013I116","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"163_CR12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-2007-979503","volume":"30","author":"T Baptista","year":"1997","unstructured":"Baptista T, Molina MG, Martinez JL, de Quijada M, Calanche de Cuesta I, Acosta A, Paez X, Martinez JM, Hernandez L (1997) Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation. Pharmacopsychiatry 30:256\u2013262","journal-title":"Pharmacopsychiatry"},{"key":"163_CR13","first-page":"1068","volume":"42","author":"T Bastiampillai","year":"2008","unstructured":"Bastiampillai T, Dhillon R, Mohindra R (2008) Exacerbation of tics secondary to clozapine therapy. Aust N Z J Psychiatry 42:1068\u20131070","journal-title":"Aust N Z J Psychiatry"},{"key":"163_CR14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1024\/\/1422-4917.28.1.35","volume":"28","author":"L Baving","year":"2000","unstructured":"Baving L, Schmidt MH (2000) Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system. Z Kinder Jugendpsychiatr Psychother 28:35\u201344","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"key":"163_CR15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1440-1614.2005.01549.x","volume":"39","author":"M Begum","year":"2005","unstructured":"Begum M (2005) Clozapine-induced stuttering, facial tics and myoclonic seizures: a case report. Aust N Z J Psychiatry 39:202","journal-title":"Aust N Z J Psychiatry"},{"key":"163_CR16","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/mds.21859","volume":"23","author":"M Ben Djebara","year":"2008","unstructured":"Ben Djebara M, Worbe Y, Schupbach M, Hartmann A (2008) Aripiprazole: a treatment for severe coprolalia in \u201crefractory\u201d Gilles de la Tourette syndrome. Mov Disord 23:438\u2013440","journal-title":"Mov Disord"},{"key":"163_CR17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00004583-200002000-00008","volume":"39","author":"Z Bengi Semerci","year":"2000","unstructured":"Bengi Semerci Z (2000) Olanzapine in Tourette\u2019s disorder. J Am Acad Child Adolesc Psychiatry 39:140","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.172.4.366a","volume":"172","author":"BR Bhadrinath","year":"1998","unstructured":"Bhadrinath BR (1998) Olanzapine in Tourette syndrome. Br J Psychiatry 172:366","journal-title":"Br J Psychiatry"},{"key":"163_CR19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11920-008-0052-z","volume":"10","author":"MH Bloch","year":"2008","unstructured":"Bloch MH (2008) Emerging treatments for Tourette\u2019s disorder. Curr Psychiatry Rep 10:323\u2013330","journal-title":"Curr Psychiatry Rep"},{"key":"163_CR20","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","volume":"11","author":"MH Bloch","year":"2006","unstructured":"Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11:622\u2013632","journal-title":"Mol Psychiatry"},{"key":"163_CR21","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/CHI.0b013e3181b26e9f","volume":"48","author":"MH Bloch","year":"2009","unstructured":"Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF (2009) Meta-analysis: treatment of attention-deficit\/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 48:884\u2013893","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archpedi.160.1.65","volume":"160","author":"MH Bloch","year":"2006","unstructured":"Bloch MH, Peterson BS, Scahill L, Otka J, Katsovich L, Zhang H, Leckman JF (2006) Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Arch Pediatr Adolesc Med 160:65\u201369","journal-title":"Arch Pediatr Adolesc Med"},{"key":"163_CR23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-2004-827171","volume":"37","author":"N Bock","year":"2004","unstructured":"Bock N, Moll GH, Wicker M, Pilz J, Ruther E, Banaschewski T, Huether G, Rothenberger A (2004) Early administration of tiapride to young rats without long-lasting changes in the development of the dopaminergic system. Pharmacopsychiatry 37:163\u2013167","journal-title":"Pharmacopsychiatry"},{"key":"163_CR24","first-page":"S156","volume":"88 Suppl 8","author":"V Boon-yasidhi","year":"2005","unstructured":"Boon-yasidhi V, Kim YS, Scahill L (2005) An open-label, prospective study of guanfacine in children with ADHD and tic disorders. J Med Assoc Thai 88 Suppl 8:S156\u2013S162","journal-title":"J Med Assoc Thai"},{"key":"163_CR25","first-page":"377","volume":"35","author":"RL Borison","year":"1982","unstructured":"Borison RL, Ang L, Chang S, Dysken M, Comaty JE, Davis JM (1982) New pharmacological approaches in the treatment of Tourette syndrome. Adv Neurol 35:377\u2013382","journal-title":"Adv Neurol"},{"key":"163_CR26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0361-9230(83)90192-2","volume":"11","author":"RL Borison","year":"1983","unstructured":"Borison RL, Ang L, Hamilton WJ, Diamond BI, Davis JM (1983) Treatment approaches in Gilles de la Tourette syndrome. Brain Res Bull 11:205\u2013208","journal-title":"Brain Res Bull"},{"key":"163_CR27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/0269881104040251","volume":"18","author":"RA Bressan","year":"2004","unstructured":"Bressan RA, Jones HM, Pilowsky LS (2004) Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity. J Psychopharmacol 18:124\u2013127","journal-title":"J Psychopharmacol"},{"key":"163_CR28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4088\/JCP.v62n0111","volume":"62","author":"R Bruggeman","year":"2001","unstructured":"Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA (2001) Risperidone versus pimozide in Tourette\u2019s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 62:50\u201356","journal-title":"J Clin Psychiatry"},{"key":"163_CR29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1176\/ajp.145.5.621","volume":"145","author":"RD Bruun","year":"1988","unstructured":"Bruun RD (1988) Subtle and underrecognized adverse reactions of neuroleptic treatment in children with Tourette\u2019s disorder. Am J Psychiatry 145:621\u2013624","journal-title":"Am J Psychiatry"},{"key":"163_CR30","first-page":"29","volume":"57","author":"RD Bruun","year":"1996","unstructured":"Bruun RD, Budman CL (1996) Risperidone as a treatment for Tourette\u2019s syndrome. J Clin Psychiatry 57:29\u201331","journal-title":"J Clin Psychiatry"},{"key":"163_CR31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/15622970500474770","volume":"7","author":"E Bubl","year":"2006","unstructured":"Bubl E, Perlov E, Tebartz Van Elst L (2006) Aripiprazole in patients with Tourette syndrome. World J Biol Psychiatry 7:123\u2013125","journal-title":"World J Biol Psychiatry"},{"key":"163_CR32","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/cap.2007.061","volume":"18","author":"C Budman","year":"2008","unstructured":"Budman C, Coffey BJ, Shechter R, Schrock M, Wieland N, Spirgel A, Simon E (2008) Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 18:509\u2013515","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4088\/JCP.v62n0412","volume":"62","author":"CL Budman","year":"2001","unstructured":"Budman CL, Gayer A, Lesser M, Shi Q, Bruun RD (2001) An open-label study of the treatment efficacy of olanzapine for Tourette\u2019s disorder. J Clin Psychiatry 62:290\u2013294","journal-title":"J Clin Psychiatry"},{"key":"163_CR34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","volume":"302","author":"KD Burris","year":"2002","unstructured":"Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381\u2013389","journal-title":"J Pharmacol Exp Ther"},{"key":"163_CR35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/ajp.136.3.317","volume":"136","author":"ED Caine","year":"1979","unstructured":"Caine ED, Polinsky RJ, Kartzinel R, Ebert MH (1979) The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 136:317\u2013320","journal-title":"Am J Psychiatry"},{"key":"163_CR36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00004583-199705000-00008","volume":"36","author":"FX Castellanos","year":"1997","unstructured":"Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, Rapoport JL (1997) Controlled stimulant treatment of ADHD and comorbid Tourette\u2019s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 36:589\u2013596","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2217\/14750708.6.2.249","volume":"6","author":"V Chang","year":"2009","unstructured":"Chang V, Friedman JH (2009) Motor adverse reactions of atypical antipsychotic drugs. Therapy 6:249\u2013258","journal-title":"Therapy"},{"key":"163_CR38","first-page":"253","volume":"58","author":"PB Chappell","year":"1992","unstructured":"Chappell PB, Leckman JF, Riddle MA, Anderson GM, Listwack SJ, Ort SI, Hardin MT, Scahill LD, Cohen DJ (1992) Neuroendocrine and behavioral effects of naloxone in Tourette syndrome. Adv Neurol 58:253\u2013262","journal-title":"Adv Neurol"},{"key":"163_CR39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0165-1781(93)90084-T","volume":"47","author":"PB Chappell","year":"1993","unstructured":"Chappell PB, Leckman JF, Scahill LD, Hardin MT, Anderson G, Cohen DJ (1993) Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette\u2019s syndrome: a pilot study. Psychiatry Res 47:267\u2013280","journal-title":"Psychiatry Res"},{"key":"163_CR40","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/00004583-199509000-00010","volume":"34","author":"PB Chappell","year":"1995","unstructured":"Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Arnsten A, Leckman JF, Cohen DJ (1995) Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette\u2019s syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 34:1140\u20131146","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00213-007-0840-x","volume":"194","author":"JY Cheng","year":"2007","unstructured":"Cheng JY, Chen RY, Ko JS, Ng EM (2007) Efficacy and safety of atomoxetine for attention-deficit\/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 194:197\u2013209","journal-title":"Psychopharmacology (Berl)"},{"key":"163_CR42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pscychresns.2003.06.001","volume":"130","author":"KA Cheon","year":"2004","unstructured":"Cheon KA, Ryu YH, Namkoong K, Kim CH, Kim JJ, Lee JD (2004) Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette\u2019s disorder. Psychiatry Res 130:85\u201395","journal-title":"Psychiatry Res"},{"key":"163_CR43","first-page":"725","volume":"58","author":"C Chouza","year":"1982","unstructured":"Chouza C, Romero S, Lorenzo J, Camano JL, Fontana AP, Alterwain P, Cibils D, Gaudiano J, Feres S, Solana J (1982) Clinical trial of tiapride in patients with dyskinesia (author\u2019s transl). Sem Hop 58:725\u2013733","journal-title":"Sem Hop"},{"key":"163_CR44","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/01.nmd.0000144696.14555.c4","volume":"192","author":"BJ Coffey","year":"2004","unstructured":"Coffey BJ, Biederman J, Geller D, Frazier J, Spencer T, Doyle R, Gianini L, Small A, Frisone DF, Magovcevic M, Stein N, Faraone SV (2004) Reexamining Tic Persistence and Tic-Associated Impairment in Tourette\u2019s Disorder: Findings From a Naturalistic Follow-Up Study. J Nerv Ment Dis 192:776\u2013780","journal-title":"J Nerv Ment Dis"},{"key":"163_CR45","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/archpsyc.1980.01780250036004","volume":"37","author":"DJ Cohen","year":"1980","unstructured":"Cohen DJ, Detlor J, Young JG, Shaywitz BA (1980) Clonidine ameliorates Gilles de la Tourette syndrome. Arch Gen Psychiatry 37:1350\u20131357","journal-title":"Arch Gen Psychiatry"},{"key":"163_CR46","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0140-6736(79)91614-3","volume":"2","author":"DJ Cohen","year":"1979","unstructured":"Cohen DJ, Young JG, Nathanson JA, Shaywitz BA (1979) Clonidine in Tourette\u2019s syndrome. Lancet 2:551\u2013553","journal-title":"Lancet"},{"key":"163_CR47","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1017\/S1461145706006833","volume":"9","author":"EL Constant","year":"2006","unstructured":"Constant EL, Borras L, Seghers A (2006) Aripiprazole is effective in the treatment of Tourette\u2019s disorder. Int J Neuropsychopharmacol 9:773\u2013774","journal-title":"Int J Neuropsychopharmacol"},{"key":"163_CR48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00044011-200727020-00005","volume":"27","author":"M Copur","year":"2007","unstructured":"Copur M, Arpaci B, Demir T, Narin H (2007) Clinical effectiveness of quetiapine in children and adolescents with Tourette\u2019s syndrome: a retrospective case-note survey. Clin Drug Investig 27:123\u2013130","journal-title":"Clin Drug Investig"},{"key":"163_CR49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/cap.2009.0125","volume":"20","author":"YH Cui","year":"2010","unstructured":"Cui YH, Zheng Y, Yang YP, Liu J, Li J (2010) Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette\u2019s disorder: a pilot study in China. J Child Adolesc Psychopharmacol 20:291\u2013298","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR50","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00002826-200211000-00009","volume":"25","author":"DD Cummings","year":"2002","unstructured":"Cummings DD, Singer HS, Krieger M, Miller TL, Mahone EM (2002) Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study. Clin Neuropharmacol 25:325\u2013332","journal-title":"Clin Neuropharmacol"},{"key":"163_CR51","doi-asserted-by":"crossref","unstructured":"Curtis A, Clarke CE, Rickards HE (2009) Cannabinoids for Tourette\u2019s Syndrome. Cochrane Database Syst Rev:CD006565","DOI":"10.1002\/14651858.CD006565.pub2"},{"key":"163_CR52","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hup.798","volume":"21","author":"L Davies","year":"2006","unstructured":"Davies L, Stern JS, Agrawal N, Robertson MM (2006) A case series of patients with Tourette\u2019s syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 21:447\u2013453","journal-title":"Hum Psychopharmacol"},{"key":"163_CR53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/chi.0b013e31815d9ae4","volume":"47","author":"WB Daviss","year":"2008","unstructured":"Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE Jr, Palumbo D, Harris P, Sallee FR (2008) Clonidine for attention-deficit\/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 47:189\u2013198","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR54","doi-asserted-by":"crossref","unstructured":"Debes N, Hjalgrim H, Skov L (2010) The presence of attention-deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder worsen psychosocial and educational problems in Tourette syndrome. J Child Neurol 25:171\u2013181","DOI":"10.1177\/0883073809336215"},{"key":"163_CR55","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1176\/appi.ajp.162.3.625","volume":"162","author":"S Dehning","year":"2005","unstructured":"Dehning S, Riedel M, Muller N (2005) Aripiprazole in a patient vulnerable to adverse reactions. Am J Psychiatry 162:625","journal-title":"Am J Psychiatry"},{"key":"163_CR56","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1192\/bjp.157.5.762","volume":"157","author":"PL Delgado","year":"1990","unstructured":"Delgado PL, Goodman WK, Price LH, Heninger GR, Charney DS (1990) Fluvoxamine\/pimozide treatment of concurrent Tourette\u2019s and obsessive-compulsive disorder. Br J Psychiatry 157:762\u2013765","journal-title":"Br J Psychiatry"},{"key":"163_CR57","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(89)91063-5","volume":"2","author":"EJ Devor","year":"1989","unstructured":"Devor EJ, Isenberg KE (1989) Nicotine and Tourette\u2019s syndrome. Lancet 2:1046","journal-title":"Lancet"},{"key":"163_CR58","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00004583-199607000-00004","volume":"35","author":"MR Diantoniis","year":"1996","unstructured":"Diantoniis MR, Henry KM, Partridge PA, Soucar E (1996) Tics and risperidone. J Am Acad Child Adolesc Psychiatry 35:839\u2013840","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR59","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1176\/jnp.5.1.108-a","volume":"5","author":"T Dimitsopulos","year":"1993","unstructured":"Dimitsopulos T, Kurlan R (1993) Tourette\u2019s syndrome and nicotine withdrawal. J Neuropsychiatry Clin Neurosci 5:108\u2013109","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"163_CR60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","volume":"22","author":"Y Dion","year":"2002","unstructured":"Dion Y, Annable L, Sandor P, Chouinard G (2002) Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 22:31\u201339","journal-title":"J Clin Psychopharmacol"},{"key":"163_CR61","first-page":"216","volume":"37","author":"I Drt\u00edlkov\u00e1","year":"1996","unstructured":"Drt\u00edlkov\u00e1 I (1996) Clonazepam, clonidine and tiapride in children with tic disorder. Homeostasis 37:216","journal-title":"Homeostasis"},{"key":"163_CR62","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/00048670802277222","volume":"42","author":"YS Du","year":"2008","unstructured":"Du YS, Li HF, Vance A, Zhong YQ, Jiao FY, Wang HM, Wang MJ, Su LY, Yu DL, Ma SW, Wu JB (2008) Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry 42:807\u2013813","journal-title":"Aust N Z J Psychiatry"},{"key":"163_CR63","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/08830738060210042403","volume":"21","author":"DD Duane","year":"2006","unstructured":"Duane DD (2006) Aripiprazole in childhood and adolescence for Tourette syndrome. J Child Neurol 21:358","journal-title":"J Child Neurol"},{"key":"163_CR64","doi-asserted-by":"crossref","first-page":"85S","DOI":"10.1097\/00004583-199710001-00007","volume":"36","author":"M Dulcan","year":"1997","unstructured":"Dulcan M (1997) Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit\/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 36:85S\u2013121S","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR65","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0140-6736(95)92564-3","volume":"345","author":"SM Dursun","year":"1995","unstructured":"Dursun SM, Burke JG, Reveley MA (1995) Buspirone treatment of Tourette\u2019s syndrome. Lancet 345:1366\u20131367","journal-title":"Lancet"},{"key":"163_CR66","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1017\/S0033291796003984","volume":"27","author":"SM Dursun","year":"1997","unstructured":"Dursun SM, Reveley MA (1997) Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette\u2019s syndrome: an open study. Psychol Med 27:483\u2013487","journal-title":"Psychol Med"},{"key":"163_CR67","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(94)90388-3","volume":"344","author":"SM Dursun","year":"1994","unstructured":"Dursun SM, Reveley MA, Bird R, Stirton F (1994) Longlasting improvement of Tourette\u2019s syndrome with transdermal nicotine. Lancet 344:1577","journal-title":"Lancet"},{"key":"163_CR68","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00449911","volume":"237","author":"C Eggers","year":"1988","unstructured":"Eggers C, Rothenberger A, Berghaus U (1988) Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 237:223\u2013229","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"163_CR69","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02125572","volume":"2","author":"C Eggers","year":"1993","unstructured":"Eggers C, Schepker R, Oades RD (1993) Exacerbation and provocation of tics by imipramine and sulpiride. Eur Child Adolesc Psychiatry 2:169\u2013176","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"163_CR70","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-1-4684-2511-6_11","volume":"90","author":"HM Erickson Jr","year":"1977","unstructured":"Erickson HM Jr, Goggin JE, Messiha FS (1977) Comparison of lithium and haloperidol therapy in Gilles de la Tourette syndrome. Adv Exp Med Biol 90:197\u2013205","journal-title":"Adv Exp Med Biol"},{"key":"163_CR71","doi-asserted-by":"crossref","unstructured":"Fernandez-Jaen A, Fernandez-Mayoralas DM, Munoz-Jareno N, Calleja-Perez B (2009) An open-label, prospective study of levetiracetam in children and adolescentes with Tourette syndrome. Eur J Paediatr Neurol","DOI":"10.1016\/j.ejpn.2008.12.006"},{"key":"163_CR72","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/1362361306063297","volume":"10","author":"C Feroz-Nainar","year":"2006","unstructured":"Feroz-Nainar C, Roy M (2006) Risperidone and late onset tics. Autism 10:302\u2013307","journal-title":"Autism"},{"key":"163_CR73","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0b013e31817dd520","volume":"28","author":"RL Findling","year":"2008","unstructured":"Findling RL, Kauffman RE, Sallee FR, Carson WH, Nyilas M, Mallikaarjun S, Shoaf SE, Forbes RA, Boulton DW, Pikalov A (2008) Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J Clin Psychopharmacol 28:441\u2013446","journal-title":"J Clin Psychopharmacol"},{"key":"163_CR74","first-page":"213","volume":"34","author":"J Forner-Valero","year":"1986","unstructured":"Forner-Valero J, Aymerich VB, Oritz-Lopez A (1986) Comperative study of the effects of tiapride and a placebo on the involuntary movements and manual ability of children with cerebromotor disorders. Neuropsychiatrie de l\u2019Enfance et de l\u2019Adolescence 34:213\u2013216","journal-title":"Neuropsychiatrie de l\u2019Enfance et de l\u2019Adolescence"},{"key":"163_CR75","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1345\/aph.1D497","volume":"38","author":"KN Fountoulakis","year":"2004","unstructured":"Fountoulakis KN, Iacovides A, St Kaprinis G (2004) Successful treatment of Tourette\u2019s disorder with amisulpride. Ann Pharmacother 38:901","journal-title":"Ann Pharmacother"},{"key":"163_CR76","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1345\/aph.1G331","volume":"40","author":"KN Fountoulakis","year":"2006","unstructured":"Fountoulakis KN, Siamouli M, Kantartzis S, Panagiotidis P, Iacovides A, Kaprinis GS (2006) Acute dystonia with low-dosage aripiprazole in Tourette\u2019s disorder. Ann Pharmacother 40:775\u2013777","journal-title":"Ann Pharmacother"},{"key":"163_CR77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004583-199601000-00004","volume":"35","author":"I Fras","year":"1996","unstructured":"Fras I (1996) Guanfacine for Tourette\u2019s disorder. J Am Acad Child Adolesc Psychiatry 35:3\u20134","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1742-1241.1970.tb03263.x","volume":"24","author":"JA Frederiks","year":"1970","unstructured":"Frederiks JA (1970) Facial tics in children: the therapeutic effect of low-dosage diazepam. Br J Clin Pract 24:17\u201320","journal-title":"Br J Clin Pract"},{"key":"163_CR79","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00787-007-1003-7","volume":"16 (Suppl 1)","author":"RD Freeman","year":"2007","unstructured":"Freeman RD (2007) Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome. Eur Child Adolesc Psychiatry 16 (Suppl 1):15\u201323","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"163_CR80","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.braindev.2005.03.009","volume":"28","author":"C Fusco","year":"2006","unstructured":"Fusco C, Bertani G, Caricati G, Della Giustina E (2006) Stress fracture of the peroneal bone secondary to a complex tic. Brain Dev 28:52\u201354","journal-title":"Brain Dev"},{"key":"163_CR81","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/ana.410210421","volume":"21","author":"N Gadoth","year":"1987","unstructured":"Gadoth N, Gordon CR, Streifler J (1987) Naloxone in Gilles de la Tourette\u2019s syndrome. Ann Neurol 21:415","journal-title":"Ann Neurol"},{"key":"163_CR82","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archpsyc.56.4.330","volume":"56","author":"KD Gadow","year":"1999","unstructured":"Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S (1999) Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry 56:330\u2013336","journal-title":"Arch Gen Psychiatry"},{"key":"163_CR83","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004583-200203000-00013","volume":"41","author":"GR Gaffney","year":"2002","unstructured":"Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S (2002) Risperidone versus clonidine in the treatment of children and adolescents with Tourette\u2019s syndrome. J Am Acad Child Adolesc Psychiatry 41:330\u2013336","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR84","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1176\/jnp.2.1.66","volume":"2","author":"S Gancher","year":"1990","unstructured":"Gancher S, Conant-Norville D, Angell R (1990) Treatment of Tourette\u2019s syndrome with transdermal clonidine: a pilot study. J Neuropsychiatry Clin Neurosci 2:66\u201369","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"163_CR85","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/hup.470080505","volume":"8","author":"MS George","year":"1993","unstructured":"George MS, Trimble MR, Robertson MM (1993) Fluvoxamine And Sulpiride In Comorbid Obsessive-Compulsive Disorder And Gilles-De-La-Tourette Syndrome. Hum Psychopharmacol Clin Exp 8:327\u2013334","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"163_CR86","first-page":"1097","volume":"152","author":"WJ Giakas","year":"1995","unstructured":"Giakas WJ (1995) Risperidone treatment for a Tourette\u2019s disorder patient with comorbid obsessive-compulsive disorder. Am J Psychiatry 152:1097\u20131098","journal-title":"Am J Psychiatry"},{"key":"163_CR87","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/08830738060210080401","volume":"21","author":"D Gilbert","year":"2006","unstructured":"Gilbert D (2006) Treatment of children and adolescents with tics and Tourette syndrome. J Child Neurol 21:690\u2013700","journal-title":"J Child Neurol"},{"key":"163_CR88","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004583-200402000-00017","volume":"43","author":"DL Gilbert","year":"2004","unstructured":"Gilbert DL, Batterson JR, Sethuraman G, Sallee FR (2004) Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 43:206\u2013214","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR89","first-page":"245","volume":"58","author":"CG Goetz","year":"1992","unstructured":"Goetz CG (1992) Clonidine and clonazepam in Tourette syndrome. Adv Neurol 58:245\u2013251","journal-title":"Adv Neurol"},{"key":"163_CR90","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mds.870090306","volume":"9","author":"CG Goetz","year":"1994","unstructured":"Goetz CG, Stebbins GT, Thelen JA (1994) Talipexole and adult Gilles de la Tourette\u2019s syndrome: double-blind, placebo-controlled clinical trial. Mov Disord 9:315\u2013317","journal-title":"Mov Disord"},{"key":"163_CR91","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/archneur.1984.04050150049015","volume":"41","author":"CG Goetz","year":"1984","unstructured":"Goetz CG, Tanner CM, Klawans HL (1984) Fluphenazine and multifocal tic disorders. Arch Neurol 41:271\u2013272","journal-title":"Arch Neurol"},{"key":"163_CR92","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ana.410210313","volume":"21","author":"CG Goetz","year":"1987","unstructured":"Goetz CG, Tanner CM, Wilson RS, Carroll VS, Como PG, Shannon KM (1987) Clonidine and Gilles de la Tourette\u2019s syndrome: double-blind study using objective rating methods. Ann Neurol 21:307\u2013310","journal-title":"Ann Neurol"},{"key":"163_CR93","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0887-8994(85)90063-3","volume":"1","author":"GS Golden","year":"1985","unstructured":"Golden GS (1985) Tardive dyskinesia in Tourette syndrome. Pediatr Neurol 1:192\u2013194","journal-title":"Pediatr Neurol"},{"key":"163_CR94","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1017\/S0317167100025129","volume":"4","author":"M Gonce","year":"1977","unstructured":"Gonce M, Barbeau A (1977) Seven cases of Gilles de la Tourette\u2019s syndrome: partial relief with clonazepam: a pilot study. Can J Neurol Sci 4:279\u2013283","journal-title":"Can J Neurol Sci"},{"key":"163_CR95","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1192\/bjp.bp.109.071050","volume":"197","author":"DA Gorman","year":"2010","unstructured":"Gorman DA, Thompson N, Plessen KJ, Robertson MM, Leckman JF, Peterson BS (2010) Psychosocial outcome and psychiatric comorbidity in older adolescents with Tourette syndrome: controlled study. Br J Psychiatry 197:36\u201344","journal-title":"Br J Psychiatry"},{"key":"163_CR96","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ajp.2008.07101574","volume":"165","author":"G Grunder","year":"2008","unstructured":"Grunder G, Fellows C, Janouschek H, Veselinovic T, Boy C, Brocheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, Rosch F, Schaefer WM, Vernaleken I (2008) Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 165:988\u2013995","journal-title":"Am J Psychiatry"},{"key":"163_CR97","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/08830738060210080901","volume":"21","author":"K Harris","year":"2006","unstructured":"Harris K, Singer HS (2006) Tic disorders: neural circuits, neurochemistry, and neuroimmunology. J Child Neurol 21:678\u2013689","journal-title":"J Child Neurol"},{"key":"163_CR98","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/JCP.0b013e3181d236ec","volume":"30","author":"A Hasan","year":"2010","unstructured":"Hasan A, Rothenberger A, Munchau A, Wobrock T, Falkai P, Roessner V (2010) Oral Delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. J Clin Psychopharmacol 30:190\u2013192","journal-title":"J Clin Psychopharmacol"},{"key":"163_CR99","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.pediatrneurol.2008.12.014","volume":"40","author":"EF Hedderick","year":"2009","unstructured":"Hedderick EF, Morris CM, Singer HS (2009) Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 40:420\u2013425","journal-title":"Pediatr Neurol"},{"key":"163_CR100","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0929-6646(09)60406-X","volume":"108","author":"CS Ho","year":"2009","unstructured":"Ho CS, Chen HJ, Chiu NC, Shen EY, Lue HC (2009) Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc 108:788\u2013793","journal-title":"J Formos Med Assoc"},{"key":"163_CR101","doi-asserted-by":"crossref","first-page":"537","DOI":"10.4088\/JCP.v65n0413","volume":"65","author":"PJ Hoekstra","year":"2004","unstructured":"Hoekstra PJ, Minderaa RB, Kallenberg CG (2004) Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. J Clin Psychiatry 65:537\u2013542","journal-title":"J Clin Psychiatry"},{"key":"163_CR102","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0165-0327(98)00183-9","volume":"54","author":"JP Horrigan","year":"1999","unstructured":"Horrigan JP, Barnhill LJ (1999) Guanfacine and secondary mania in children. J Affect Disord 54:309\u2013314","journal-title":"J Affect Disord"},{"key":"163_CR103","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1590\/S1516-44462004000300015","volume":"26","author":"A Hounie","year":"2004","unstructured":"Hounie A, De Mathis A, Sampaio AS, Mercadante MT (2004) Aripiprazole and Tourette syndrome. Rev Bras Psiquiatr 26:213","journal-title":"Rev Bras Psiquiatr"},{"key":"163_CR104","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.eurpsy.2003.11.002","volume":"19","author":"AL Howson","year":"2004","unstructured":"Howson AL, Batth S, Ilivitsky V, Boisjoli A, Jaworski M, Mahoney C, Knott VJ (2004) Clinical and attentional effects of acute nicotine treatment in Tourette\u2019s syndrome. Eur Psychiatry 19:102\u2013112","journal-title":"Eur Psychiatry"},{"key":"163_CR105","first-page":"26","volume":"30","author":"TL Huang","year":"2007","unstructured":"Huang TL, Lu CY (2007) Correlations between weight changes and lipid profile changes in schizophrenic patients after antipsychotics therapy. Chang Gung Med J 30:26\u201332","journal-title":"Chang Gung Med J"},{"key":"163_CR106","doi-asserted-by":"crossref","unstructured":"Ikenouchi-Sugita A, Yoshimura R, Hayashi K, Ueda N, Umene-Nakano W, Hori H, Nakamura J (2009) A case of late-onset Tourette\u2019s disorder successfully treated with aripiprazole: View from blood levels of catecholamine metabolites and brain-derived neurotrophic factor (BDNF). World J Biol Psychiatry 1\u20134","DOI":"10.1080\/15622970902718147"},{"key":"163_CR107","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/mds.870090315","volume":"9","author":"J Jankovic","year":"1994","unstructured":"Jankovic J (1994) Botulinum toxin in the treatment of dystonic tics. Mov Disord 9:347\u2013349","journal-title":"Mov Disord"},{"key":"163_CR108","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","volume":"48","author":"J Jankovic","year":"1997","unstructured":"Jankovic J, Beach J (1997) Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48:358\u2013362","journal-title":"Neurology"},{"key":"163_CR109","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/WNL.34.5.688","volume":"34","author":"J Jankovic","year":"1984","unstructured":"Jankovic J, Glaze DG, Frost JD Jr (1984) Effect of tetrabenazine on tics and sleep of Gilles de la Tourette\u2019s syndrome. Neurology 34:688\u2013692","journal-title":"Neurology"},{"key":"163_CR110","doi-asserted-by":"crossref","unstructured":"Jankovic J, Jimenez-Shahed J, Brown L (2010) A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 81:70\u201373","DOI":"10.1136\/jnnp.2009.185348"},{"key":"163_CR111","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1212\/WNL.38.3.391","volume":"38","author":"J Jankovic","year":"1988","unstructured":"Jankovic J, Orman J (1988) Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 38:391\u2013394","journal-title":"Neurology"},{"key":"163_CR112","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1017\/S0317167100038087","volume":"14","author":"J Jankovic","year":"1987","unstructured":"Jankovic J, Rohaidy H (1987) Motor, behavioral and pharmacologic findings in Tourette\u2019s syndrome. Can J Neurol Sci 14:541\u2013546","journal-title":"Can J Neurol Sci"},{"key":"163_CR113","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","volume":"441","author":"S Jordan","year":"2002","unstructured":"Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137\u2013140","journal-title":"Eur J Pharmacol"},{"key":"163_CR114","unstructured":"Joy CB, Adams CE, Lawrie SM (2006) Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev CD003082"},{"key":"163_CR115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0361-9230(83)90194-6","volume":"11","author":"B Kaim","year":"1983","unstructured":"Kaim B (1983) A case of Gilles de la Tourette\u2019s syndrome treated with clonazepam. Brain Res Bull 11:213\u2013214","journal-title":"Brain Res Bull"},{"key":"163_CR116","first-page":"537","volume":"11","author":"H Kang","year":"2009","unstructured":"Kang H, Zhang YF, Jiao FY, Guo XY, Gao XM (2009) Efficacy of clonidine transdermal patch for treatment of Tourette\u2019s syndrome in children. Zhongguo Dang Dai Er Ke Za Zhi 11:537\u2013539","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"163_CR117","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00004583-200002000-00007","volume":"39","author":"M Karam-Hage","year":"2000","unstructured":"Karam-Hage M, Ghaziuddin N (2000) Olanzapine in Tourette\u2019s disorder. J Am Acad Child Adolesc Psychiatry 39:139","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR118","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/01.jcp.0000150229.69124.66","volume":"25","author":"A Kastrup","year":"2005","unstructured":"Kastrup A, Schlotter W, Plewnia C, Bartels M (2005) Treatment of tics in tourette syndrome with aripiprazole. J Clin Psychopharmacol 25:94\u201396","journal-title":"J Clin Psychopharmacol"},{"key":"163_CR119","unstructured":"Kawohl W, Schneider F, Vernaleken I, Neuner I (2008) Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients. World J Biol Psychiatry 1\u20135"},{"key":"163_CR120","unstructured":"Kenney CJ, Hunter CB, Mejia NI, Jankovic J (2007) Tetrabenazine in the treatment of Tourette syndrome J Pediatr Neurol 5 9\u201313"},{"key":"163_CR121","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0149-7634(88)80052-6","volume":"12","author":"J Kerbeshian","year":"1988","unstructured":"Kerbeshian J, Burd L (1988) Differential responsiveness to lithium in patients with Tourette disorder. Neurosci Biobehav Rev 12:247\u2013250","journal-title":"Neurosci Biobehav Rev"},{"key":"163_CR122","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/cap.2005.15.318","volume":"15","author":"BN Kim","year":"2005","unstructured":"Kim BN, Lee CB, Hwang JW, Shin MS, Cho SC (2005) Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea. J Child Adolesc Psychopharmacol 15:318\u2013324","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR123","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/mds.20738","volume":"21","author":"A King","year":"2006","unstructured":"King A, Harris P, Fritzell J, Kurlan R (2006) Syncope in children with Tourette\u2019s syndrome treated with guanfacine. Mov Disord 21:419\u2013420","journal-title":"Mov Disord"},{"key":"163_CR124","first-page":"516","volume":"40","author":"H Klepel","year":"1988","unstructured":"Klepel H, Gebelt H, Koch RD, Tzenow H (1988) Treatment of extrapyramidal hyperkineses in childhood with tiapride. Psychiatr Neurol Med Psychol (Leipz) 40:516\u2013522","journal-title":"Psychiatr Neurol Med Psychol (Leipz)"},{"key":"163_CR125","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/mds.870110512","volume":"11","author":"JK Krauss","year":"1996","unstructured":"Krauss JK, Jankovic J (1996) Severe motor tics causing cervical myelopathy in Tourette\u2019s syndrome. Mov Disord 11:563\u2013566","journal-title":"Mov Disord"},{"key":"163_CR126","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/cap.1998.8.107","volume":"8","author":"J Krishnamoorthy","year":"1998","unstructured":"Krishnamoorthy J, King BH (1998) Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol 8:107\u2013113","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR127","doi-asserted-by":"crossref","unstructured":"Kuo SH, Jimenez-Shahed J (2010) Topiramate in Treatment of Tourette Syndrome. Clin Neuropharmacol 33:32\u201334","DOI":"10.1097\/WNF.0b013e3181c295c1"},{"key":"163_CR128","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0733-8619(05)70321-2","volume":"15","author":"R Kurlan","year":"1997","unstructured":"Kurlan R (1997) Tourette syndrome. Treatment of tics. Neurol Clin 15:403\u2013409","journal-title":"Neurol Clin"},{"key":"163_CR129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ana.410300105","volume":"30","author":"R Kurlan","year":"1991","unstructured":"Kurlan R, Majumdar L, Deeley C, Mudholkar GS, Plumb S, Como PG (1991) A controlled trial of propoxyphene and naltrexone in patients with Tourette\u2019s syndrome. Ann Neurol 30:19\u201323","journal-title":"Ann Neurol"},{"key":"163_CR130","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.57.8.1383","volume":"57","author":"R Kurlan","year":"2001","unstructured":"Kurlan R, McDermott MP, Deeley C, Como PG, Brower C, Eapen S, Andresen EM, Miller B (2001) Prevalence of tics in schoolchildren and association with placement in special education. Neurology 57:1383\u20131388","journal-title":"Neurology"},{"key":"163_CR131","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archneur.57.8.1190","volume":"57","author":"CH Kwak","year":"2000","unstructured":"Kwak CH, Hanna PA, Jankovic J (2000) Botulinum toxin in the treatment of tics. Arch Neurol 57:1190\u20131193","journal-title":"Arch Neurol"},{"key":"163_CR132","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)11526-1","volume":"360","author":"JF Leckman","year":"2002","unstructured":"Leckman JF (2002) Tourette\u2019s syndrome. Lancet 360:1577\u20131586","journal-title":"Lancet"},{"key":"163_CR133","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/WNL.35.3.343","volume":"35","author":"JF Leckman","year":"1985","unstructured":"Leckman JF, Detlor J, Harcherik DF, Ort S, Shaywitz BA, Cohen DJ (1985) Short- and long-term treatment of Tourette\u2019s syndrome with clonidine: a clinical perspective. Neurology 35:343\u2013351","journal-title":"Neurology"},{"key":"163_CR134","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/archpsyc.1991.01810280040006","volume":"48","author":"JF Leckman","year":"1991","unstructured":"Leckman JF, Hardin MT, Riddle MA, Stevenson J, Ort SI, Cohen DJ (1991) Clonidine treatment of Gilles de la Tourette\u2019s syndrome. Arch Gen Psychiatry 48:324\u2013328","journal-title":"Arch Gen Psychiatry"},{"key":"163_CR135","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/00004583-198907000-00015","volume":"28","author":"JF Leckman","year":"1989","unstructured":"Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ (1989) The yale global tic severity scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566\u2013573","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR136","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/cap.2005.15.331","volume":"15","author":"M Ledbetter","year":"2005","unstructured":"Ledbetter M (2005) Atomoxetine use associated with onset of a motor tic. J Child Adolesc Psychopharmacol 15:331\u2013333","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR137","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/088307389601100205","volume":"11","author":"DG Lichter","year":"1996","unstructured":"Lichter DG, Jackson LA (1996) Predictors of clonidine response in Tourette syndrome: implications and inferences. J Child Neurol 11:93\u201397","journal-title":"J Child Neurol"},{"key":"163_CR138","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1176\/ajp.142.5.613","volume":"142","author":"LS Linet","year":"1985","unstructured":"Linet LS (1985) Tourette syndrome, pimozide, and school phobia: the neuroleptic separation anxiety syndrome. Am J Psychiatry 142:613\u2013615","journal-title":"Am J Psychiatry"},{"key":"163_CR139","first-page":"695","volume":"59","author":"A Lipcsey","year":"1983","unstructured":"Lipcsey A (1983) Gilles de la Tourette\u2019s disease. Sem Hop 59:695\u2013696","journal-title":"Sem Hop"},{"key":"163_CR140","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/00004583-199509000-00011","volume":"34","author":"PJ Lombroso","year":"1995","unstructured":"Lombroso PJ, Scahill L, King RA, Lynch KA, Chappell PB, Peterson BS, McDougle CJ, Leckman JF (1995) Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 34:1147\u20131152","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR141","first-page":"129","volume":"30","author":"MT Lucas Taracena","year":"2002","unstructured":"Lucas Taracena MT, Montanes Rada F (2002) Olanzapine in Tourette\u2019s syndrome: a report of three cases. Actas Esp Psiquiatr 30:129\u2013132","journal-title":"Actas Esp Psiquiatr"},{"key":"163_CR142","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/cap.2009.0035","volume":"19","author":"GJ Lyon","year":"2009","unstructured":"Lyon GJ, Samar S, Jummani R, Hirsch S, Spirgel A, Goldman R, Coffey BJ (2009) Aripiprazole in children and adolescents with Tourette\u2019s disorder: an open-label safety and tolerability study. J Child Adolesc Psychopharmacol 19:623\u2013633","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR143","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.4088\/JCP.v63n1115","volume":"63","author":"HC Margolese","year":"2002","unstructured":"Margolese HC, Annable L, Dion Y (2002) Depression and dysphoria in adult and adolescent patients with Tourette\u2019s disorder treated with risperidone. J Clin Psychiatry 63:1040\u20131044","journal-title":"J Clin Psychiatry"},{"key":"163_CR144","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1212\/WNL.56.5.605","volume":"56","author":"C Marras","year":"2001","unstructured":"Marras C, Andrews D, Sime E, Lang AE (2001) Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 56:605\u2013610","journal-title":"Neurology"},{"key":"163_CR145","first-page":"517","volume":"54","author":"JF Mathe","year":"1978","unstructured":"Mathe JF, Cler JM, Venisse JL (1978) Therapeutic use of tiapride in movement disorders. Sem Hop 54:517\u2013520","journal-title":"Sem Hop"},{"key":"163_CR146","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1176\/ajp.148.6.793","volume":"148","author":"BJ McConville","year":"1991","unstructured":"McConville BJ, Fogelson MH, Norman AB, Klykylo WM, Manderscheid PZ, Parker KW, Sanberg PR (1991) Nicotine potentiation of haloperidol in reducing tic frequency in Tourette\u2019s disorder. Am J Psychiatry 148:793\u2013794","journal-title":"Am J Psychiatry"},{"key":"163_CR147","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/0006-3223(92)90315-Q","volume":"31","author":"BJ McConville","year":"1992","unstructured":"McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW, Norman AB (1992) The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette\u2019s disorder. Biol Psychiatry 31:832\u2013840","journal-title":"Biol Psychiatry"},{"key":"163_CR148","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/cap.2007.135","volume":"18","author":"JT McCracken","year":"2008","unstructured":"McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J (2008) Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol 18:501\u2013508","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR149","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00004714-199310000-00008","volume":"13","author":"CJ McDougle","year":"1993","unstructured":"McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH (1993) The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol 13:354\u2013358","journal-title":"J Clin Psychopharmacol"},{"key":"163_CR150","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0140-6736(81)92103-6","volume":"1","author":"IG McKeith","year":"1981","unstructured":"McKeith IG, Williams A, Nicol AR (1981) Clonidine in Tourette syndrome. Lancet 1:270\u2013271","journal-title":"Lancet"},{"key":"163_CR151","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/mds.20218","volume":"19","author":"A Meisel","year":"2004","unstructured":"Meisel A, Winter C, Zschenderlein R, Arnold G (2004) Tourette syndrome: efficient treatment with ziprasidone and normalization of body weight in a patient with excessive weight gain under tiapride. Mov Disord 19:991\u2013992","journal-title":"Mov Disord"},{"key":"163_CR152","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1600-0447.1985.tb02628.x","volume":"72","author":"JR Merikangas","year":"1985","unstructured":"Merikangas JR, Merikangas KR, Kopp U, Hanin I (1985) Blood choline and response to clonazepam and haloperidol in Tourette\u2019s syndrome. Acta Psychiatr Scand 72:395\u2013399","journal-title":"Acta Psychiatr Scand"},{"key":"163_CR153","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4088\/JCP.v63n0509","volume":"63","author":"JM Meyer","year":"2002","unstructured":"Meyer JM (2002) A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1\u00a0year. J Clin Psychiatry 63:425\u2013433","journal-title":"J Clin Psychiatry"},{"key":"163_CR154","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1176\/ajp.138.12.1572","volume":"138","author":"EJ Mikkelsen","year":"1981","unstructured":"Mikkelsen EJ, Detlor J, Cohen DJ (1981) School avoidance and social phobia triggered by haloperidol in patients with Tourette\u2019s disorder. Am J Psychiatry 138:1572\u20131576","journal-title":"Am J Psychiatry"},{"key":"163_CR155","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.4088\/JCP.v68n1210","volume":"68","author":"D Miller del","year":"2007","unstructured":"Miller del D, Eudicone JM, Pikalov A, Kim E (2007) Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J Clin Psychiatry 68:1901\u20131906","journal-title":"J Clin Psychiatry"},{"key":"163_CR156","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/mds.870050119","volume":"5","author":"LG Miller","year":"1990","unstructured":"Miller LG, Jankovic J (1990) Sulpiride-induced tardive dystonia. Mov Disord 5:83\u201384","journal-title":"Mov Disord"},{"key":"163_CR157","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jns.2003.12.006","volume":"219","author":"K Minzer","year":"2004","unstructured":"Minzer K, Lee O, Hong JJ, Singer HS (2004) Increased prefrontal D2 protein in Tourette syndrome: a postmortem analysis of frontal cortex and striatum. J Neurol Sci 219:55\u201361","journal-title":"J Neurol Sci"},{"key":"163_CR158","first-page":"773","volume":"135","author":"CM Miranda","year":"2007","unstructured":"Miranda CM, Castiglioni TC (2007) Aripiprazole for the treatment of Tourette syndrome. Experience in 10 patients. Rev Med Chil 135:773\u2013776","journal-title":"Rev Med Chil"},{"key":"163_CR159","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/104454603322572624","volume":"13","author":"NM Mukaddes","year":"2003","unstructured":"Mukaddes NM, Abali O (2003) Quetiapine treatment of children and adolescents with Tourette\u2019s disorder. J Child Adolesc Psychopharmacol 13:295\u2013299","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR160","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neulet.2005.05.031","volume":"385","author":"KR Muller-Vahl","year":"2005","unstructured":"Muller-Vahl KR, Meyer GJ, Knapp WH, Emrich HM, Gielow P, Brucke T, Berding G (2005) Serotonin transporter binding in Tourette Syndrome. Neurosci Lett 385:120\u2013125","journal-title":"Neurosci Lett"},{"key":"163_CR161","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/sj.npp.1300047","volume":"28","author":"KR Muller-Vahl","year":"2003","unstructured":"Muller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U (2003) Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 28:384\u2013388","journal-title":"Neuropsychopharmacology"},{"key":"163_CR162","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-2002-25028","volume":"35","author":"KR Muller-Vahl","year":"2002","unstructured":"Muller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T, Emrich HM (2002) Treatment of Tourette\u2019s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57\u201361","journal-title":"Pharmacopsychiatry"},{"key":"163_CR163","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/ajp.156.3.495","volume":"156","author":"KR Muller-Vahl","year":"1999","unstructured":"Muller-Vahl KR, Schneider U, Kolbe H, Emrich HM (1999) Treatment of Tourette\u2019s syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 156:495","journal-title":"Am J Psychiatry"},{"key":"163_CR164","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","volume":"64","author":"KR Muller-Vahl","year":"2003","unstructured":"Muller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM (2003) Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459\u2013465","journal-title":"J Clin Psychiatry"},{"key":"163_CR165","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1163\/1568560042342338","volume":"12","author":"N Muller","year":"2004","unstructured":"Muller N (2004) Anti-inflammatory therapy with a COX-2 inhibitor in Tourette\u2019s syndrome. Inflammopharmacol 12:271\u2013275","journal-title":"Inflammopharmacol"},{"key":"163_CR166","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1017\/S1461145705005365","volume":"8","author":"TK Murphy","year":"2005","unstructured":"Murphy TK, Bengtson MA, Soto O, Edge PJ, Sajid MW, Shapira N, Yang M (2005) Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol 8:489\u2013490","journal-title":"Int J Neuropsychopharmacol"},{"key":"163_CR167","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1089\/cap.2008.0149","volume":"19","author":"TK Murphy","year":"2009","unstructured":"Murphy TK, Mutch PJ, Reid JM, Edge PJ, Storch EA, Bengtson M, Yang M (2009) Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol 19:441\u2013447","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR168","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1542\/peds.73.6.841","volume":"73","author":"JP Neglia","year":"1984","unstructured":"Neglia JP, Glaze DG, Zion TE (1984) Tics and vocalizations in children treated with carbamazepine. Pediatrics 73:841\u2013844","journal-title":"Pediatrics"},{"key":"163_CR169","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/01.chi.0000163279.39598.44","volume":"44","author":"R Nicolson","year":"2005","unstructured":"Nicolson R, Craven-Thuss B, Smith J, McKinlay BD, Castellanos FX (2005) A randomized, double-blind, placebo-controlled trial of metoclopramide for the treatment of Tourette\u2019s disorder. J Am Acad Child Adolesc Psychiatry 44:640\u2013646","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR170","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/0883073807307108","volume":"23","author":"WG Ondo","year":"2008","unstructured":"Ondo WG, Jong D, Davis A (2008) Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs. J Child Neurol 23:435\u2013437","journal-title":"J Child Neurol"},{"key":"163_CR171","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s004150070173","volume":"247","author":"M Onofrj","year":"2000","unstructured":"Onofrj M, Paci C, D\u2019Andreamatteo G, Toma L (2000) Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind crossover study vs. low-dose pimozide. J Neurol 247:443\u2013446","journal-title":"J Neurol"},{"key":"163_CR172","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/brain\/awh473","volume":"128","author":"M Orth","year":"2005","unstructured":"Orth M, Amann B, Robertson MM, Rothwell JC (2005) Excitability of motor cortex inhibitory circuits in Tourette syndrome before and after single dose nicotine. Brain 128:1292\u20131300","journal-title":"Brain"},{"key":"163_CR173","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4088\/PCC.v07n0605","volume":"7","author":"PR Padala","year":"2005","unstructured":"Padala PR, Qadri SF, Madaan V (2005) Aripiprazole for the treatment of Tourette\u2019s disorder. Prim Care Companion J Clin Psychiatry 7:296\u2013299","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"163_CR174","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.wnf.0000136892.24629.96","volume":"27","author":"D Paleacu","year":"2004","unstructured":"Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S (2004) Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 27:230\u2013233","journal-title":"Clin Neuropharmacol"},{"key":"163_CR175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/1044546041649138","volume":"14","author":"D Palumbo","year":"2004","unstructured":"Palumbo D, Spencer T, Lynch J, Co-Chien H, Faraone SV (2004) Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol 14:185\u2013194","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR176","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.mp.4001040","volume":"7","author":"L Pani","year":"2002","unstructured":"Pani L, Gessa GL (2002) The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Mol Psychiatry 7:247\u2013253","journal-title":"Mol Psychiatry"},{"key":"163_CR177","first-page":"27","volume":"15","author":"E Pappadopulos","year":"2006","unstructured":"Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS (2006) Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. J Can Acad Child Adolesc Psychiatry 15:27\u201339","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"163_CR178","first-page":"E1","volume":"13","author":"HC Parraga","year":"2008","unstructured":"Parraga HC, Parraga KL, Harris DK, Campbell TS (2008) Abdominal tics during atomoxetine treatment in a child with ADHD: evaluation and differential diagnosis. CNS Spectr 13:E1","journal-title":"CNS Spectr"},{"key":"163_CR179","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/070674370104600220","volume":"46","author":"HC Parraga","year":"2001","unstructured":"Parraga HC, Parraga MI (2001) Quetiapine treatment in patients with Tourette syndrome. Can J Psychiatry 46:184\u2013185","journal-title":"Can J Psychiatry"},{"key":"163_CR180","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2190\/PM.37.4.e","volume":"37","author":"HC Parraga","year":"2007","unstructured":"Parraga HC, Parraga MI, Harris DK (2007) Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder. Int J Psychiatry Med 37:415\u2013424","journal-title":"Int J Psychiatry Med"},{"key":"163_CR181","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/104454601750284108","volume":"11","author":"HC Parraga","year":"2001","unstructured":"Parraga HC, Parraga MI, Woodward RL, Fenning PA (2001) Quetiapine treatment of children with Tourette\u2019s syndrome: report of two cases. J Child Adolesc Psychopharmacol 11:187\u2013191","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR182","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00004583-200104000-00005","volume":"40","author":"HC Parraga","year":"2001","unstructured":"Parraga HC, Woodward RL (2001) Quetiapine for Tourette\u2019s syndrome. J Am Acad Child Adolesc Psychiatry 40:389\u2013391","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR183","first-page":"645","volume":"25","author":"C Pasquier","year":"1977","unstructured":"Pasquier C, Pouplard F (1977) Reflections on child tics. Apropos of a therapeutic trial. Rev Neuropsychiatr Infant 25:645\u2013651","journal-title":"Rev Neuropsychiatr Infant"},{"key":"163_CR184","doi-asserted-by":"crossref","unstructured":"Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, Martinez-Garcia O, Vazquez-Barquero JL, Crespo-Facorro B (2009) Glucose and lipid disturbances after 1\u00a0year of antipsychotic treatment in a drug-naive population. Schizophr Res 107:115\u2013121","DOI":"10.1016\/j.schres.2008.09.028"},{"key":"163_CR185","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(98)12297-3","volume":"354","author":"SJ Perlmutter","year":"1999","unstructured":"Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, Swedo SE (1999) Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 354:1153\u20131158","journal-title":"Lancet"},{"key":"163_CR186","unstructured":"Pierce A, Rickards H (in press) Atypical Antipsychotics for Tourette\u2019s Syndrome. Cochrane Database Syst Rev"},{"key":"163_CR187","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10072-003-0201-4","volume":"24","author":"M Porta","year":"2004","unstructured":"Porta M, Maggioni G, Ottaviani F, Schindler A (2004) Treatment of phonic tics in patients with Tourette\u2019s syndrome using botulinum toxin type A. Neurol Sci 24:420\u2013423","journal-title":"Neurol Sci"},{"key":"163_CR188","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00044011-200828070-00006","volume":"28","author":"M Porta","year":"2008","unstructured":"Porta M, Sassi M, Cavallazzi M, Fornari M, Brambilla A, Servello D (2008) Tourette\u2019s syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig 28:443\u2013459","journal-title":"Clin Drug Investig"},{"key":"163_CR189","doi-asserted-by":"crossref","unstructured":"Pringsheim T, Marras C (2009) Pimozide for tics in Tourette\u2019s syndrome. Cochrane Database Syst Rev CD006996","DOI":"10.1002\/14651858.CD006996.pub2"},{"key":"163_CR190","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.parkreldis.2009.11.011","volume":"16","author":"JJ Rath","year":"2010","unstructured":"Rath JJ, Tavy DL, Wertenbroek AA, van Woerkom TC, de Bruijn SF (2010) Botulinum toxin type A in simple motor tics: short-term and long-term treatment-effects. Parkinsonism Relat Disord 16:478\u2013481","journal-title":"Parkinsonism Relat Disord"},{"key":"163_CR191","first-page":"343","volume":"85","author":"MA Riddle","year":"2001","unstructured":"Riddle MA, Carlson J (2001) Clinical psychopharmacology for Tourette syndrome and associated disorders. Adv Neurol 85:343\u2013354","journal-title":"Adv Neurol"},{"key":"163_CR192","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1987.01800130110023","volume":"44","author":"MA Riddle","year":"1987","unstructured":"Riddle MA, Hardin MT, Towbin KE, Leckman JF, Cohen DJ (1987) Tardive dyskinesia following haloperidol treatment in Tourette\u2019s syndrome. Arch Gen Psychiatry 44:98\u201399","journal-title":"Arch Gen Psychiatry"},{"key":"163_CR193","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1017\/S0317167100029541","volume":"16","author":"DE Riley","year":"1989","unstructured":"Riley DE, Lang AE (1989) Pain in Gilles de la Tourette syndrome and related tic disorders. Can J Neurol Sci 16:439\u2013441","journal-title":"Can J Neurol Sci"},{"key":"163_CR194","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jpsychores.2008.03.007","volume":"65","author":"MM Robertson","year":"2008","unstructured":"Robertson MM (2008) The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 2: tentative explanations for differing prevalence figures in GTS, including the possible effects of psychopathology, aetiology, cultural differences, and differing phenotypes. J Psychosom Res 65:473\u2013486","journal-title":"J Psychosom Res"},{"key":"163_CR195","doi-asserted-by":"crossref","unstructured":"Robertson MM (2000) Tourette syndrome, associated conditions and the complexities of treatment. Brain 123 Pt 3:425\u2013462","DOI":"10.1093\/brain\/123.3.425"},{"key":"163_CR196","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jpsychores.2009.07.010","volume":"67","author":"MM Robertson","year":"2009","unstructured":"Robertson MM, Eapen V, Cavanna AE (2009) The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res 67:475\u2013483","journal-title":"J Psychosom Res"},{"key":"163_CR197","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00002826-199006000-00005","volume":"13","author":"MM Robertson","year":"1990","unstructured":"Robertson MM, Schnieden V, Lees AJ (1990) Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 13:229\u2013235","journal-title":"Clin Neuropharmacol"},{"key":"163_CR198","doi-asserted-by":"crossref","unstructured":"Robertson MM, Scull DA, Eapen V, Trimble MR (1996) Risperidone in the treatment of Tourette syndrome: A retrospective case note study. Psychopharmacol 10:317\u2013320","DOI":"10.1177\/026988119601000411"},{"key":"163_CR199","unstructured":"Robertson MM, Stern JS (2000) Gilles de la Tourette syndrome: symptomatic treatment based on evidence. Eur Child Adolesc Psychiatry 9 (Suppl 1):I60\u2013I75"},{"key":"163_CR200","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00702-007-0817-2","volume":"115","author":"V Roessner","year":"2008","unstructured":"Roessner V, Banaschewski T, Fillmer-Otte A, Becker A, Albrecht B, Uebel H, Sergeant J, Tannock R, Rothenberger A (2008) Color perception deficits in co-existing attention-deficit\/hyperactivity disorder and chronic tic disorders. J Neural Transm 115:235\u2013239","journal-title":"J Neural Transm"},{"key":"163_CR201","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00787-007-1005-5","volume":"16 (Suppl 1)","author":"V Roessner","year":"2007","unstructured":"Roessner V, Becker A, Banaschewski T, Rothenberger A (2007) Executive functions in children with chronic tic disorders with\/without ADHD: new insights. Eur Child Adolesc Psychiatry 16 (Suppl 1):36\u201344","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"163_CR202","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10802-006-9086-z","volume":"35","author":"V Roessner","year":"2007","unstructured":"Roessner V, Becker A, Banaschewski T, Rothenberger A (2007) Psychopathological profile in children with chronic tic disorder and co-existing ADHD: additive effects. J Abnorm Child Psychol 35:79\u201385","journal-title":"J Abnorm Child Psychol"},{"key":"163_CR203","doi-asserted-by":"crossref","unstructured":"Roessner V, Becker A, Banaschewski T, Rothenberger A (2005) Tic disorders and obsessive compulsive disorder: where is the link? J Neural Transm Suppl 69:69\u201399","DOI":"10.1007\/3-211-31222-6_5"},{"key":"163_CR204","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1017\/S0012162206001290","volume":"48","author":"V Roessner","year":"2006","unstructured":"Roessner V, Robatzek M, Knapp G, Banaschewski T, Rothenberger A (2006) First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol 48:616\u2013621","journal-title":"Dev Med Child Neurol"},{"key":"163_CR205","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/cap.2008.0120","volume":"19","author":"Y Roke","year":"2009","unstructured":"Roke Y, van Harten PN, Boot AM, Buitelaar JK (2009) Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated adverse reactions. J Child Adolesc Psychopharmacol 19:403\u2013414","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR206","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1176\/ajp.135.5.585","volume":"135","author":"MS Ross","year":"1978","unstructured":"Ross MS, Moldofsky H (1978) A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette\u2019s syndrome. Am J Psychiatry 135:585\u2013587","journal-title":"Am J Psychiatry"},{"key":"163_CR207","unstructured":"Rothenberger A, Banaschewski T, Roessner V (2007) Tic-St\u00f6rungen. In: Deutsche Gesellschaft f\u00fcr Kinder- u. Jugendpsychiatrie PuP (ed) Leitlinien zur Diagnostik und Therapie von psychischen St\u00f6rungen im S\u00e4uglings-, Kindes- und Jugendalter. Deutscher \u00c4rzteverlag, K\u00f6ln, pp 319\u2013325"},{"key":"163_CR208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00787-007-1001-9","volume":"16 (Suppl 1)","author":"A Rothenberger","year":"2007","unstructured":"Rothenberger A, Roessner V, Banaschewski T, Leckman JF (2007) Co-existence of tic disorders and attention-deficit\/hyperactivity disorder-recent advances in understanding and treatment. Eur Child Adolesc Psychiatry 16 (Suppl 1):1\u20134","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"163_CR209","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-2007-979218","volume":"32","author":"E Ruther","year":"1999","unstructured":"Ruther E, Degner D, Munzel U, Brunner E, Lenhard G, Biehl J, Vogtle-Junkert U (1999) Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry 32:127\u2013135","journal-title":"Pharmacopsychiatry"},{"key":"163_CR210","doi-asserted-by":"crossref","unstructured":"Sallee F, McGough J, Wigal T, Donahue J, Lyne A, Biederman J (2009) Guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:155\u2013165","DOI":"10.1097\/CHI.0b013e318191769e"},{"key":"163_CR211","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/01.CHI.0000046897.27264.46","volume":"42","author":"FR Sallee","year":"2003","unstructured":"Sallee FR, Gilbert DL, Vinks AA, Miceli JJ, Robarge L, Wilner K (2003) Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission. J Am Acad Child Adolesc Psychiatry 42:902\u2013907","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR212","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","volume":"39","author":"FR Sallee","year":"2000","unstructured":"Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB (2000) Ziprasidone treatment of children and adolescents with Tourette\u2019s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39:292\u2013299","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR213","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/01.chi.0000215347.93902.3e","volume":"45","author":"FR Sallee","year":"2006","unstructured":"Sallee FR, Miceli JJ, Tensfeldt T, Robarge L, Wilner K, Patel NC (2006) Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:720\u2013728","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR214","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1176\/ajp.154.8.1057","volume":"154","author":"FR Sallee","year":"1997","unstructured":"Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G (1997) Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette\u2019s disorder. Am J Psychiatry 154:1057\u20131062","journal-title":"Am J Psychiatry"},{"key":"163_CR215","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/mds.870110627","volume":"11","author":"S Salloway","year":"1996","unstructured":"Salloway S, Stewart CF, Israeli L, Morales X, Rasmussen S, Blitzer A, Brin MF (1996) Botulinum toxin for refractory vocal tics. Mov Disord 11:746\u2013748","journal-title":"Mov Disord"},{"key":"163_CR216","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(88)91388-8","volume":"1","author":"PR Sanberg","year":"1988","unstructured":"Sanberg PR, Fogelson HM, Manderscheid PZ, Parker KW, Norman AB, McConville BJ (1988) Nicotine gum and haloperidol in Tourette\u2019s syndrome. Lancet 1:592","journal-title":"Lancet"},{"key":"163_CR217","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0022-3999(03)00060-6","volume":"55","author":"P Sandor","year":"2003","unstructured":"Sandor P (2003) Pharmacological management of tics in patients with TS. J Psychosom Res 55:41\u201348","journal-title":"J Psychosom Res"},{"key":"163_CR218","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00004714-199006000-00007","volume":"10","author":"P Sandor","year":"1990","unstructured":"Sandor P, Musisi S, Moldofsky H, Lang A (1990) Tourette syndrome: a follow-up study. J Clin Psychopharmacol 10:197\u2013199","journal-title":"J Clin Psychopharmacol"},{"key":"163_CR219","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00004714-200012000-00025","volume":"20","author":"P Sandor","year":"2000","unstructured":"Sandor P, Stephens RJ (2000) Risperidone treatment of aggressive behavior in children with Tourette syndrome. J Clin Psychopharmacol 20:710\u2013712","journal-title":"J Clin Psychopharmacol"},{"key":"163_CR220","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ana.410180322","volume":"18","author":"R Sandyk","year":"1985","unstructured":"Sandyk R (1985) The effects of naloxone in Tourette\u2019s syndrome. Ann Neurol 18:367\u2013368","journal-title":"Ann Neurol"},{"key":"163_CR221","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/00207458708987115","volume":"35","author":"R Sandyk","year":"1987","unstructured":"Sandyk R (1987) Naloxone abolishes obsessive-compulsive behavior in Tourette\u2019s syndrome. Int J Neurosci 35:93\u201394","journal-title":"Int J Neurosci"},{"key":"163_CR222","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00004714-198602000-00029","volume":"6","author":"R Sandyk","year":"1986","unstructured":"Sandyk R (1986) Naloxone withdrawal exacerbates Tourette syndrome. J Clin Psychopharmacol 6:58\u201359","journal-title":"J Clin Psychopharmacol"},{"key":"163_CR223","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","volume":"158","author":"L Scahill","year":"2001","unstructured":"Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AF, Cohen DJ, Leckman JF (2001) A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 158:1067\u20131074","journal-title":"Am J Psychiatry"},{"key":"163_CR224","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1056-4993(18)30137-8","volume":"9","author":"L Scahill","year":"2000","unstructured":"Scahill L, Chappell PB, King RA, Leckman JF (2000) Pharmacologic treatment of tic disorders. Child Adolesc Psychiatr Clin N Am 9:99\u2013117","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"163_CR225","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.nurx.2006.01.009","volume":"3","author":"L Scahill","year":"2006","unstructured":"Scahill L, Erenberg G, Berlin CM Jr, Budman C, Coffey BJ, Jankovic J, Kiessling L, King RA, Kurlan R, Lang A, Mink J, Murphy T, Zinner S, Walkup J (2006) Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 3:192\u2013206","journal-title":"NeuroRx"},{"key":"163_CR226","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","volume":"60","author":"L Scahill","year":"2003","unstructured":"Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130\u20131135","journal-title":"Neurology"},{"key":"163_CR227","doi-asserted-by":"crossref","first-page":"29s","DOI":"10.1016\/S0924-9338(00)00526-5","volume":"16 Suppl 1","author":"B Scatton","year":"2001","unstructured":"Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R (2001) The preclinical pharmacologic profile of tiapride. Eur Psychiatry 16 Suppl 1:29s\u201334s","journal-title":"Eur Psychiatry"},{"key":"163_CR228","unstructured":"Schlander M, Schwarz O, Rothenberger A, Roessner V Tic disorders: prevalence and co-occurrence with attention-deficit\/hyperactivity disorder in a German community sample. Eur Psychiatry. (in press)"},{"key":"163_CR229","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mds.870110413","volume":"11","author":"BL Scott","year":"1996","unstructured":"Scott BL, Jankovic J, Donovan DT (1996) Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette\u2019s syndrome. Mov Disord 11:431\u2013433","journal-title":"Mov Disord"},{"key":"163_CR230","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1017\/S1092852900016412","volume":"13","author":"J Sears","year":"2008","unstructured":"Sears J, Patel NC (2008) Development of tics in a thirteen-year-old male following atomoxetine use. CNS Spectr 13:301\u2013303","journal-title":"CNS Spectr"},{"key":"163_CR231","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S0387-7604(03)90011-8","volume":"25 (Suppl 1)","author":"M Segawa","year":"2003","unstructured":"Segawa M (2003) Neurophysiology of Tourette\u2019s syndrome: pathophysiological considerations. Brain Dev 25 (Suppl 1):S62\u2013S69","journal-title":"Brain Dev"},{"key":"163_CR232","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/cap.2007.0064","volume":"18","author":"WS Seo","year":"2008","unstructured":"Seo WS, Sung HM, Sea HS, Bai DS (2008) Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 18:197\u2013205","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR233","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.0001-690X.2004.00214.x","volume":"109","author":"J Serra-Mestres","year":"2004","unstructured":"Serra-Mestres J, Ring H, Costa D (2004) Dopamine transporter binding in Gilles de la Tourette syndrome: A [123I]FP-CIT\/SPECT study. Acta Psychiatr Scand 109:140\u2013146","journal-title":"Acta Psychiatr Scand"},{"key":"163_CR234","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/archpsyc.1983.01790100081011","volume":"40","author":"AK Shapiro","year":"1983","unstructured":"Shapiro AK, Shapiro E, Eisenkraft GJ (1983) Treatment of Gilles de la Tourette\u2019s syndrome with clonidine and neuroleptics. Arch Gen Psychiatry 40:1235\u20131240","journal-title":"Arch Gen Psychiatry"},{"key":"163_CR235","first-page":"127","volume-title":"Giles de la Tourette syndrome","author":"AK Shapiro","year":"1988","unstructured":"Shapiro AK, Shapiro ES, Young JG, Feinberg TE (1988) Measurement in tic disorders. In: Shapiro AK, Shapiro ES, Young JG, Feinberg TE (eds) Giles de la Tourette syndrome. Raven Press, New York, pp 127\u2013193"},{"key":"163_CR236","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","volume":"46","author":"E Shapiro","year":"1989","unstructured":"Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, Phillips RA (1989) Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette\u2019s syndrome. Arch Gen Psychiatry 46:722\u2013730","journal-title":"Arch Gen Psychiatry"},{"key":"163_CR237","first-page":"267","volume-title":"Tourette syndrome and tic disorders","author":"E Shapiro","year":"1998","unstructured":"Shapiro E, Shapiro E (1998) Treatment of tic disorders with haloperidol. In: Cohen DJ, Bruun RD, Leckman JF (eds) Tourette syndrome and tic disorders. Wiley, New York, pp 267\u2013280"},{"key":"163_CR238","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1212\/WNL.45.7.1419","volume":"45","author":"LM Shulman","year":"1995","unstructured":"Shulman LM, Singer C, Weiner WJ (1995) Risperidone in Gilles de la Tourette syndrome. Neurology 45:1419","journal-title":"Neurology"},{"key":"163_CR239","doi-asserted-by":"crossref","unstructured":"Shytle RD, Silver AA, Philipp MK, McConville BJ, Sanberg PR (1996) Transdermal nicotine for Tourette\u2019s syndrome. Drug Dev Res 38:290\u2013298","DOI":"10.1002\/(SICI)1098-2299(199607\/08)38:3\/4<290::AID-DDR18>3.0.CO;2-2"},{"key":"163_CR240","unstructured":"Silay YS, Vuong KD, Jankovic J (2004) The efficacy and safety of fluphenazine in patients with Tourette syndrome: P06.128. Neurology 62:A506"},{"key":"163_CR241","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/cap.1993.3.137","volume":"3","author":"RR Silva","year":"1993","unstructured":"Silva RR, Magee HJ, Friedhoff AJ (1993) Persistent tardive dyskinesia and other neuroleptic-related dyskinesias in Tourette\u2019s disorder. J Child Adoles Psychopharmacol 3:137\u2013144","journal-title":"J Child Adoles Psychopharmacol"},{"key":"163_CR242","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0140-6736(93)91392-Y","volume":"342","author":"AA Silver","year":"1993","unstructured":"Silver AA, Sanberg PR (1993) Transdermal nicotine patch and potentiation of haloperidol in Tourette\u2019s syndrome. Lancet 342:182","journal-title":"Lancet"},{"key":"163_CR243","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/00004583-199612000-00015","volume":"35","author":"AA Silver","year":"1996","unstructured":"Silver AA, Shytle RD, Philipp MK, Sanberg PR (1996) Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette\u2019s syndrome. J Am Acad Child Adolesc Psychiatry 35:1631\u20131636","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR244","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-3-0348-7445-8_38","volume-title":"The effects of nicotine on biological systems","author":"AA Silver","year":"1995","unstructured":"Silver AA, Shytle RD, Philipp MK, Sanberg PR (1995) Transdermal nicotine in Tourette\u2019s Syndrome. In: Clarke PBS, Quik M, Thurau K (eds) The effects of nicotine on biological systems. Birkhauser Publishers, Boston, pp 293\u2013299"},{"key":"163_CR245","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4088\/JCP.v62n0908","volume":"62","author":"AA Silver","year":"2001","unstructured":"Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR (2001) Transdermal nicotine and haloperidol in Tourette\u2019s disorder: a double-blind placebo-controlled study. J Clin Psychiatry 62:707\u2013714","journal-title":"J Clin Psychiatry"},{"key":"163_CR246","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11940-010-0095-4","volume":"12","author":"HS Singer","year":"2010","unstructured":"Singer HS (2010) Treatment of tics and Tourette syndrome. Curr Treat Options Neurol 12:539\u2013561","journal-title":"Curr Treat Options Neurol"},{"key":"163_CR247","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1542\/peds.95.1.74","volume":"95","author":"HS Singer","year":"1995","unstructured":"Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB (1995) The treatment of attention-deficit hyperactivity disorder in Tourette\u2019s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 95:74\u201381","journal-title":"Pediatrics"},{"key":"163_CR248","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000120222","volume":"12","author":"HS Singer","year":"1985","unstructured":"Singer HS, Gammon K, Quaskey S (1985) Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci 12:71\u201374","journal-title":"Pediatr Neurosci"},{"key":"163_CR249","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ana.410300408","volume":"30","author":"HS Singer","year":"1991","unstructured":"Singer HS, Hahn IH, Moran TH (1991) Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette\u2019s syndrome. Ann Neurol 30:558\u2013562","journal-title":"Ann Neurol"},{"key":"163_CR250","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1176\/appi.ajp.159.8.1329","volume":"159","author":"HS Singer","year":"2002","unstructured":"Singer HS, Szymanski S, Giuliano J, Yokoi F, Dogan AS, Brasic JR, Zhou Y, Grace AA, Wong DF (2002) Elevated intrasynaptic dopamine release in Tourette\u2019s syndrome measured by PET. Am J Psychiatry 159:1329\u20131336","journal-title":"Am J Psychiatry"},{"key":"163_CR251","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1212\/WNL.56.5.599","volume":"56","author":"HS Singer","year":"2001","unstructured":"Singer HS, Wendlandt J, Krieger M, Giuliano J (2001) Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology 56:599\u2013604","journal-title":"Neurology"},{"key":"163_CR252","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/mds.870030313","volume":"3","author":"SK Singh","year":"1988","unstructured":"Singh SK, Jankovic J (1988) Tardive dystonia in patients with Tourette\u2019s syndrome. Mov Disord 3:274\u2013280","journal-title":"Mov Disord"},{"key":"163_CR253","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/mds.21615","volume":"22","author":"CL Smith-Hicks","year":"2007","unstructured":"Smith-Hicks CL, Bridges DD, Paynter NP, Singer HS (2007) A double-blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord 22:1764\u20131770","journal-title":"Mov Disord"},{"key":"163_CR254","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.biopsych.2004.12.035","volume":"57","author":"LA Snider","year":"2005","unstructured":"Snider LA, Lougee L, Slattery M, Grant P, Swedo SE (2005) Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. Biol Psychiatry 57:788\u2013792","journal-title":"Biol Psychiatry"},{"key":"163_CR255","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archpsyc.59.7.649","volume":"59","author":"T Spencer","year":"2002","unstructured":"Spencer T, Biederman J, Coffey B, Geller D, Crawford M, Bearman SK, Tarazi R, Faraone SV (2002) A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit\/hyperactivity disorder. Arch Gen Psychiatry 59:649\u2013656","journal-title":"Arch Gen Psychiatry"},{"key":"163_CR256","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1087054707306109","volume":"11","author":"TJ Spencer","year":"2008","unstructured":"Spencer TJ, Sallee FR, Gilbert DL, Dunn DW, McCracken JT, Coffey BJ, Budman CL, Ricardi RK, Leonard HL, Allen AJ, Milton DR, Feldman PD, Kelsey DK, Geller DA, Linder SL, Lewis DW, Winner PK, Kurlan RM, Mintz M (2008) Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 11:470\u2013481","journal-title":"J Atten Disord"},{"key":"163_CR257","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00405-006-0200-1","volume":"264","author":"S Srirompotong","year":"2007","unstructured":"Srirompotong S, Saeseow P, Kharmwan S, Srirompotong S (2007) Ear wiggling tics: treatment with botulinum toxin injection. Eur Arch Otorhinolaryngol 264:385\u2013387","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"163_CR258","first-page":"298","volume":"302","author":"SM Stahl","year":"1980","unstructured":"Stahl SM, Berger PA (1980) Physostigmine in Gilles de la Tourette\u2019s syndrome. N Engl J Med 302:298","journal-title":"N Engl J Med"},{"key":"163_CR259","first-page":"240","volume":"138","author":"SM Stahl","year":"1981","unstructured":"Stahl SM, Berger PA (1981) Physostigmine in Tourette syndrome: evidence for cholinergic underactivity. Am J Psychiatry 138:240\u2013242","journal-title":"Am J Psychiatry"},{"key":"163_CR260","first-page":"6","volume":"64 Suppl 19","author":"SM Stahl","year":"2003","unstructured":"Stahl SM, Shayegan DK (2003) The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 64 Suppl 19:6\u201312","journal-title":"J Clin Psychiatry"},{"key":"163_CR261","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(94)90389-1","volume":"344","author":"M Stamenkovic","year":"1994","unstructured":"Stamenkovic M, Aschauer H, Kasper S (1994) Risperidone for Tourette\u2019s syndrome. Lancet 344:1577\u20131578","journal-title":"Lancet"},{"key":"163_CR262","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004850-200015010-00003","volume":"15","author":"M Stamenkovic","year":"2000","unstructured":"Stamenkovic M, Schindler SD, Aschauer HN, De Zwaan M, Willinger U, Resinger E, Kasper S (2000) Effective open-label treatment of tourette\u2019s disorder with olanzapine. Int Clin Psychopharmacol 15:23\u201328","journal-title":"Int Clin Psychopharmacol"},{"key":"163_CR263","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ana.21809","volume":"67","author":"TD Steeves","year":"2010","unstructured":"Steeves TD, Ko JH, Kideckel DM, Rusjan P, Houle S, Sandor P, Lang AE, Strafella AP (2010) Extrastriatal dopaminergic dysfunction in Tourette syndrome. Ann Neurol 67:170\u2013181","journal-title":"Ann Neurol"},{"key":"163_CR264","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00004583-199403000-00014","volume":"33","author":"RJ Steingard","year":"1994","unstructured":"Steingard RJ, Goldberg M, Lee D, DeMaso DR (1994) Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. J Am Acad Child Adolesc Psychiatry 33:394\u2013399","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR265","unstructured":"Stenstrom AD, Sindo I (2008) Aripiprazole for the treatment of Tourette\u2019s syndrome. Ugeskr Laeger 170:58"},{"key":"163_CR266","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.yic.0000166405.49473.70","volume":"20","author":"C Stollberger","year":"2005","unstructured":"Stollberger C, Huber JO, Finsterer J (2005) Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 20:243\u2013251","journal-title":"Int Clin Psychopharmacol"},{"key":"163_CR267","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/chi.0b013e318068fbcc","volume":"46","author":"JE Swain","year":"2007","unstructured":"Swain JE, Scahill L, Lombroso PJ, King RA, Leckman JF (2007) Tourette syndrome and tic disorders: a decade of progress. J Am Acad Child Adolesc Psychiatry 46:947\u2013968","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"163_CR268","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archpsyc.1974.01760180095012","volume":"31","author":"RD Sweet","year":"1974","unstructured":"Sweet RD, Bruun R, Shapiro E, Shapiro AK (1974) Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine. Arch Gen Psychiatry 31:857\u2013861","journal-title":"Arch Gen Psychiatry"},{"key":"163_CR269","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4103\/0028-3886.48799","volume":"57","author":"N Thomas","year":"2009","unstructured":"Thomas N, Swamidhas P, Russell S, Angothu H (2009) Tardive dyskinesia following risperidone treatment in Tourette\u2019s syndrome. Neurol India 57:94\u201395","journal-title":"Neurol India"},{"key":"163_CR270","first-page":"153","volume":"30","author":"M Toru","year":"1976","unstructured":"Toru M, Moriya H, Yamamoto K, Shimazono Y (1976) A double-blind comparison of sulpiride with chlordiazepoxide in neurosis. Folia Psychiatr Neurol Jpn 30:153\u2013164","journal-title":"Folia Psychiatr Neurol Jpn"},{"key":"163_CR271","doi-asserted-by":"crossref","unstructured":"Tourette Syndrome Study Group (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58:527\u2013536","DOI":"10.1212\/WNL.58.4.527"},{"key":"163_CR272","first-page":"175","volume":"19","author":"M Trillet","year":"1990","unstructured":"Trillet M, Moreau T, Dalery J, de Villard R, Aimard G (1990) Treatment of Gilles de la Tourette\u2019s disease with amisulpride. Presse Med 19:175","journal-title":"Presse Med"},{"key":"163_CR273","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/mds.870130348","volume":"13","author":"MR Trimble","year":"1998","unstructured":"Trimble MR, Whurr R, Brookes G, Robertson MM (1998) Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord 13:617\u2013619","journal-title":"Mov Disord"},{"key":"163_CR274","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/00007611-198809000-00009","volume":"81","author":"DD Troung","year":"1988","unstructured":"Troung DD, Bressman S, Shale H, Fahn S (1988) Clonazepam, haloperidol, and clonidine in tic disorders. South Med J 81:1103\u20131105","journal-title":"South Med J"},{"key":"163_CR275","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/mds.870090617","volume":"9","author":"C Linden van der","year":"1994","unstructured":"van der Linden C, Bruggeman R, van Woerkom TC (1994) Serotonin-dopamine antagonist and Gilles de la Tourette\u2019s syndrome: an open pilot dose-titration study with risperidone. Mov Disord 9:687\u2013688","journal-title":"Mov Disord"},{"key":"163_CR276","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/1531-8257(200011)15:6<1252::AID-MDS1030>3.0.CO;2-I","volume":"15","author":"PJ Wattum van","year":"2000","unstructured":"van Wattum PJ, Chappell PB, Zelterman D, Scahill LD, Leckman JF (2000) Patterns of response to acute naloxone infusion in Tourette\u2019s syndrome. Mov Disord 15:1252\u20131254","journal-title":"Mov Disord"},{"key":"163_CR277","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0361-9230(83)90193-4","volume":"11","author":"SK Varma","year":"1983","unstructured":"Varma SK, Messiha FS (1983) Endocrine aspects of lithium therapy in Tourette\u2019s syndrome. Brain Res Bull 11:209\u2013211","journal-title":"Brain Res Bull"},{"key":"163_CR278","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/BF00718027","volume":"235","author":"P Vieregge","year":"1987","unstructured":"Vieregge P (1987) Tetrabenazine in the treatment of senile vocal tics. J Neurol 235:126\u2013127","journal-title":"J Neurol"},{"key":"163_CR279","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jvoice.2006.08.014","volume":"22","author":"DA Vincent Jr","year":"2008","unstructured":"Vincent DA Jr (2008) Botulinum toxin in the management of laryngeal tics. J Voice 22:251\u2013256","journal-title":"J Voice"},{"key":"163_CR280","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1176\/ajp.144.4.504","volume":"144","author":"P Weiden","year":"1987","unstructured":"Weiden P, Bruun R (1987) Worsening of Tourette\u2019s disorder due to neuroleptic-induced akathisia. Am J Psychiatry 144:504\u2013505","journal-title":"Am J Psychiatry"},{"key":"163_CR281","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00004714-199908000-00006","volume":"19","author":"T Wetterling","year":"1999","unstructured":"Wetterling T, Mussigbrodt HE (1999) Weight gain: adverse reaction of atypical neuroleptics? J Clin Psychopharmacol 19:316\u2013321","journal-title":"J Clin Psychopharmacol"},{"key":"163_CR282","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1046\/j.1365-2125.2000.00148.x","volume":"49 Suppl 1","author":"KD Wilner","year":"2000","unstructured":"Wilner KD, Tensfeldt TG, Baris B, Smolarek TA, Turncliff RZ, Colburn WA, Hansen RA (2000) Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol 49 Suppl 1:15S\u201320S","journal-title":"Br J Clin Pharmacol"},{"key":"163_CR283","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/JCP.0b013e31817d86cc","volume":"28","author":"C Winter","year":"2008","unstructured":"Winter C, Heinz A, Kupsch A, Strohle A (2008) Aripiprazole in a case presenting with Tourette syndrome and obsessive-compulsive disorder. J Clin Psychopharmacol 28:452\u2013454","journal-title":"J Clin Psychopharmacol"},{"key":"163_CR284","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/cap.1993.3.175","volume":"3","author":"DV Wolf","year":"1993","unstructured":"Wolf DV, Wagner KD (1993) Tardive dyskinesia, tardive dystonia, and tardive Tourette\u2019s syndrome in children and adolescents. J Child Adoles Psychopharmacol 3:175\u2013198","journal-title":"J Child Adoles Psychopharmacol"},{"key":"163_CR285","first-page":"1243","volume":"38","author":"DF Wong","year":"1997","unstructured":"Wong DF, Singer HS, Brandt J, Shaya E, Chen C, Brown J, Kimball AW, Gjedde A, Dannals RF, Ravert HT, Wilson PD, Wagner HN Jr (1997) D2-like dopamine receptor density in Tourette syndrome measured by PET. J Nucl Med 38:1243\u20131247","journal-title":"J Nucl Med"},{"key":"163_CR286","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/01.mnm.0000239485.53780.16","volume":"27","author":"CB Yeh","year":"2006","unstructured":"Yeh CB, Lee CH, Chou YH, Chang CJ, Ma KH, Huang WS (2006) Evaluating dopamine transporter activity with 99\u00a0mTc-TRODAT-1 SPECT in drug-naive Tourette\u2019s adults. Nucl Med Commun 27:779\u2013784","journal-title":"Nucl Med Commun"},{"key":"163_CR287","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pscychresns.2007.01.003","volume":"156","author":"CB Yeh","year":"2007","unstructured":"Yeh CB, Lee CS, Ma KH, Lee MS, Chang CJ, Huang WS (2007) Phasic dysfunction of dopamine transmission in Tourette\u2019s syndrome evaluated with (99m)Tc TRODAT-1 imaging. Psychiatry Res 156:75\u201382","journal-title":"Psychiatry Res"},{"key":"163_CR288","first-page":"1088","volume":"68","author":"HK Yoo","year":"2007","unstructured":"Yoo HK, Choi SH, Park S, Wang HR, Hong JP, Kim CY (2007) An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry 68:1088\u20131093","journal-title":"J Clin Psychiatry"},{"key":"163_CR289","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1089\/cap.2006.16.505","volume":"16","author":"HK Yoo","year":"2006","unstructured":"Yoo HK, Kim JY, Kim CY (2006) A pilot study of aripiprazole in children and adolescents with Tourette\u2019s disorder. J Child Adolesc Psychopharmacol 16:505\u2013506","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"163_CR290","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jns.2007.01.069","volume":"255","author":"DY Yoon","year":"2007","unstructured":"Yoon DY, Gause CD, Leckman JF, Singer HS (2007) Frontal dopaminergic abnormality in Tourette syndrome: a postmortem analysis. J Neurol Sci 255:50\u201356","journal-title":"J Neurol Sci"},{"key":"163_CR291","first-page":"439","volume":"59","author":"M Yvonneau","year":"1970","unstructured":"Yvonneau M, Bezard P (1970) Apropos of a case of Gilles de la Tourette\u2019s disease blocked by sulpiride. Psycho-biological study. Encephale 59:439\u2013459","journal-title":"Encephale"},{"key":"163_CR292","first-page":"1105","volume":"47","author":"Z Zawadzki","year":"1972","unstructured":"Zawadzki Z (1972) Carbamazepine in the treatment of the maladie des tics. Pediatr Pol 47:1105\u20131110","journal-title":"Pediatr Pol"},{"key":"163_CR293","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11055-009-9184-9","volume":"39","author":"VP Zykov","year":"2009","unstructured":"Zykov VP, Shcherbina AY, Novikova EB, Shvabrina TV (2009) Neuroimmune aspects of the pathogenesis of Tourette\u2019s syndrome and experience in the use of immunoglobulins in children. Neurosci Behav Physiol 39:635\u2013638","journal-title":"Neurosci Behav Physiol"}],"container-title":["European Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00787-011-0163-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T13:44:21Z","timestamp":1712324661000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00787-011-0163-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,29]]},"references-count":293,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["163"],"URL":"https:\/\/doi.org\/10.1007\/s00787-011-0163-7","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,29]]}}}